JPM Healthcare Conference 2026

San Francisco, CA
January 12 – 13, 2026

Monday, January 12

Policy Breakfast (8:30 AM – 10:30 AM)
The Price of Drugs: An International Affair
Co-hosted with Incubate

In 2026, for the first time in the United States, the price of 10 medicines will be set by the federal government, an approach already in use by many other developed countries. The US is considering additional approaches to attempt to lower prices, such as international referencing, changes to intellectual property, and direct-to-consumer models. This panel will reflect on future actions policymakers in the US may take and address China’s rise as a global power in biotech and what it means for US leadership in the biotech industry.

Join us for a dynamic breakfast panel during the JP Morgan Healthcare Conference at The Hibernia, where our speakers will explore:

• International responses to US drug pricing policy: How other countries are likely to react to efforts to equalize prices in the US
• Trade and tariff: Anticipated interactions with trade policy and US pricing policy and international intellectual property protection
• Intervention on pricing practices: What to expect as US policymakers address other countries’ “willingness-to-pay thresholds” to help reduce drug prices in the US
• Investor assessment: How seriously are investors considering US pricing policy, intellectual property and its implications in their valuations?
• Administration autonomy: What can the Administration do alone without input from Congress to affect pricing and access in the US? Which channels and therapeutics are most likely affected by CMS, Trade, and the USPTO?

Life Sciences Lunch (12:00 PM – 2:00 PM)
Navigating Life Science Exit Transactions: Trends in IPOs, M&A and Strategic Collaborations
Lessons learned from 2025 and what to expect in 2026
Co-hosted with Alvarez & Marsal

Economic volatility, regulatory shifts, and persistent geopolitical tensions continued to shape the investment landscape in 2025. Despite these headwinds, the life sciences sector demonstrated resilience, with investors backing companies that delivered patient impact and scientific innovation. This panel will explore life science exit transactions and look forward to 2026 for ways to unlock the value from those 2025 investments. We will discuss IPOs, M&A and strategic collaborations or license agreements. Panelists will share insights from IPO leaders and M&A and licensing partners, alongside strategic commentary from an experienced investment banker.

Quantum Program (3:00 PM – 5:00 PM)
Why Does Biopharma Need Quantum Now?

This past year has fundamentally changed how drugs are brought to market, from government oversight to pricing strategies to the international landscape. In these new market conditions, the computational advantages of quantum are no longer a luxury but a necessity. Learn how quantum computers are solving problems today that are beyond the scope of classical computers, how large pharmaceutical companies are already investing in the market, and how emergent quantum companies are already shortening the path to commercial success in drug discovery. Following this discussion, participants are invited to network and connect with leaders in the quantum space.

Late Night Finance Reception (9:00 PM – 12:00 AM)

Please join the DLA Piper Finance team for our annual after-hours party featuring handcrafted cocktails, late night snacks and networking with the leading healthcare and life sciences lenders, investors and companies.

Tuesday, January 13

Healthcare Lunch (12:00 PM – 2:00 PM)
The Future of Healthcare: AI, Innovation, and System Transformation in 2026

As we enter 2026, artificial intelligence is no longer a peripheral tool – it’s a central force reshaping and verging on disrupting traditional healthcare delivery solutions and investment strategy. From predictive analytics and digital pathology to virtual care and platform consolidation, AI is driving a new era of transformation across the healthcare ecosystem.

Join us for a dynamic lunch panel during the JP Morgan Healthcare Conference at The Hibernia, where our speakers will explore:

• AI integration in healthcare devices: How providers are embedding AI into clinical workflows, diagnostics, and patient engaiongement platforms
• B2C best use cases: How AI-enabled services are disrupting traditional healthcare relationships with patients and consumers
• Investment outlook: What investors are watching in the AI-healthcare convergence, including M&A trends and venture-backed innovation
• Regulatory and policy shifts: Navigating the evolving landscape of antitrust enforcement, data governance, and reimbursement models
• System consolidation and platformization: The rise of tech-enabled service platforms and the implications for payors, providers, and patients

Client Cocktail Reception (5:00 PM – 8:00PM)

We hope you will join us to reconnect over cocktails and hors d’oeuvres as we gather with industry professionals and invite you to get to know our partners and colleagues.